These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 18499100

  • 21. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [Abstract] [Full Text] [Related]

  • 22. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M, Yu DM, O'Connor S, Gorrell MD.
    Clin Sci (Lond); 2009 Sep 28; 118(1):31-41. PubMed ID: 19780719
    [Abstract] [Full Text] [Related]

  • 23. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R.
    Horm Metab Res; 2004 Feb 28; 36(2):111-5. PubMed ID: 15002062
    [Abstract] [Full Text] [Related]

  • 24. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan 28; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 25. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse.
    Mustad VA, Demichele S, Huang YS, Mika A, Lubbers N, Berthiaume N, Polakowski J, Zinker B.
    Metabolism; 2006 Oct 28; 55(10):1365-74. PubMed ID: 16979408
    [Abstract] [Full Text] [Related]

  • 26. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ.
    Gastroenterology; 2010 Sep 28; 139(3):857-68. PubMed ID: 20546737
    [Abstract] [Full Text] [Related]

  • 27. [Alogliptin].
    Tanabe A, Kaku K.
    Nihon Rinsho; 2011 May 28; 69(5):871-6. PubMed ID: 21595274
    [Abstract] [Full Text] [Related]

  • 28. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
    Nonogaki K, Kaji T.
    Diabetes Metab; 2015 Nov 28; 41(5):425-8. PubMed ID: 26234524
    [Abstract] [Full Text] [Related]

  • 29. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK, Suffoletta TJ, Jennings HR.
    Pharmacotherapy; 2007 Aug 28; 27(8):1163-80. PubMed ID: 17655515
    [Abstract] [Full Text] [Related]

  • 30. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
    Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS.
    Diabetes; 2007 Jun 28; 56(6):1671-9. PubMed ID: 17369525
    [Abstract] [Full Text] [Related]

  • 31. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.
    J Pharmacol Exp Ther; 2005 Nov 28; 315(2):688-95. PubMed ID: 16027230
    [Abstract] [Full Text] [Related]

  • 32. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
    Moritoh Y, Takeuchi K, Hazama M.
    Diabetes Obes Metab; 2010 Mar 28; 12(3):224-33. PubMed ID: 20151999
    [Abstract] [Full Text] [Related]

  • 33. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
    Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B.
    Diabetes Obes Metab; 2008 Jun 28; 10(6):506-13. PubMed ID: 18284437
    [Abstract] [Full Text] [Related]

  • 34. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
    Yang SJ, Choi JM, Kim L, Kim BJ, Sohn JH, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park CY.
    Biochem Biophys Res Commun; 2011 Apr 01; 407(1):153-7. PubMed ID: 21371430
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B, Foley JE.
    Int J Clin Pract Suppl; 2008 Mar 01; (159):8-14. PubMed ID: 18269436
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.